Live Breaking News & Updates on Revumenib Syndx 5613

Stay updated with breaking news from Revumenib syndx 5613 . Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Revumenib Demonstrates Activity in Pediatric Patients With KMT2A+ Acute Leukemia

Phase 2 data from the AUGMENT-101 study show that revumenib elicits responses with acceptable safety in pediatric patients with KMT2A+ acute leukemia. ....

Zuid Holland , United States , C Michel Zwaan , Syndax Pharmaceuticals , American Society Of Pediatric Hematology Oncology , Phase 2 Augment 101 Study , 2024 American Society Of Pediatric Hematology Oncology , Ct04065399 , Kmt2a Rearranged Acute Leukemia , Revumenib Syndx 5613 ,